Ashton Thomas Securities LLC Makes New $37,000 Investment in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Ashton Thomas Securities LLC purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 73 shares of the company’s stock, valued at approximately $37,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Crewe Advisors LLC bought a new stake in shares of IDEXX Laboratories during the 1st quarter valued at $26,000. Ridgewood Investments LLC bought a new position in IDEXX Laboratories in the 2nd quarter valued at about $27,000. Institutional & Family Asset Management LLC bought a new position in IDEXX Laboratories in the 2nd quarter valued at about $28,000. E Fund Management Hong Kong Co. Ltd. raised its position in shares of IDEXX Laboratories by 5,700.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after buying an additional 57 shares in the last quarter. Finally, Mowery & Schoenfeld Wealth Management LLC lifted its holdings in shares of IDEXX Laboratories by 750.0% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after acquiring an additional 60 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently issued reports on IDXX. Barclays decreased their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Stifel Nicolaus decreased their price target on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research note on Thursday, October 10th. BTIG Research started coverage on IDEXX Laboratories in a report on Thursday, July 25th. They set a “buy” rating and a $580.00 price target for the company. JPMorgan Chase & Co. reduced their price objective on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Finally, Piper Sandler reissued a “neutral” rating and set a $435.00 target price (down previously from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $552.38.

IDEXX Laboratories Trading Up 0.9 %

Shares of NASDAQ IDXX opened at $429.82 on Thursday. The firm has a 50 day moving average price of $471.09 and a two-hundred day moving average price of $484.18. The stock has a market cap of $35.20 billion, a P/E ratio of 41.45, a price-to-earnings-growth ratio of 3.72 and a beta of 1.36. IDEXX Laboratories, Inc. has a 52-week low of $404.74 and a 52-week high of $583.39. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business had revenue of $975.50 million during the quarter, compared to analyst estimates of $980.32 million. During the same period last year, the company earned $2.53 EPS. IDEXX Laboratories’s revenue for the quarter was up 6.6% compared to the same quarter last year. As a group, equities analysts forecast that IDEXX Laboratories, Inc. will post 10.43 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.